A carregar...
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal E...
Na minha lista:
| Publicado no: | Clin Kidney J |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577767/ https://ncbi.nlm.nih.gov/pubmed/33123352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfaa198 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|